Vericel forecasts $344M-$346M 2026 revenue while raising adjusted EBITDA margin guidance to ~28% (NASDAQ:VCEL)
Vericel (VCEL) reported Q3 2026 revenue of over $85M, marking a record. The company raised its adjusted EBITDA margin guidance to ~28% and forecasted 2026 revenue between $344M-$346M, according to CEO Dominick C. Colangelo.
How this was made
The 30-second read
Why it matters
The upward revision of both revenue and EBITDA margin provides a fresh catalyst that could move the stock in the short term.
Market read
New guidance for a small‑cap biotech can drive notable price action, especially in after‑hours trading.
What to watch
Potential regulatory or clinical trial risks not addressed in the guidance could temper upside.
Background
Vericel (NASDAQ: VCEL) is a small‑cap biotech focused on cell therapies. The company reported record Q3 revenue of >$85M and now provides its 2026 outlook.
Ticker impact
Vericel disclosed 2026 revenue guidance of $344M‑$346M and raised adjusted EBITDA margin guidance to ~28%, a fresh corporate forecast.
likely upward pressure as market prices in the higher revenue and margin outlook
The new guidance exceeds prior expectations and is the first public disclosure, providing a clear catalyst for price movement.
Market effects
Biotech sector may see modest uplift as a peer raises guidance.
US biotech investors could re‑price similar small‑cap companies.
Limited to investors tracking US‑listed biotech stocks.
Counterpoint
If the guidance is already priced in, the stock may face a sell‑off on profit‑taking.
Key entities
- companyVericel
US‑listed biotech firm issuing new guidance.
